Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
J P Finberg, T Takeshima, J M Johnston, J W Commissiong
Index: Neuroreport 9(4) , 703-7, (1998)
Full Text: HTML
Abstract
Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been primed with 10% serum for 12 h (p < 0.05). Rasagiline, but not deprenyl, also increased total neuronal (MAP2-positive) survival (p < 0.05) Under serum-free conditions, rasagiline, but not deprenyl, retained its neuroprotective action on dopaminergic neurones. GABAergic neurons were not affected by either deprenyl or rasagiline. Clorgyline, an MAO-A inhibitor, did not exert any of these effects. The protective action of rasagiline on dopaminergic neurons, even under stringent serum-free conditions, is striking, and warrants further investigation for a role in the treatment of Parkinson's disease.
Related Compounds
Related Articles:
2005-01-01
[Lancet 365(9463) , 947-54, (2005)]
2000-01-01
[Clin. Neuropharmacol. 23(6) , 324-30, (2000)]
2015-09-01
[Neurobiol. Aging 36 , 2628-36, (2015)]
2015-05-01
[J. Pharmacol. Exp. Ther. 356 , 483-92, (2016)]